<?xml version="1.0" ?>
<document id="131902a67f5e00ae13b9239427325dfd53413349">
  <chunk id="131902a67f5e00ae13b9239427325dfd53413349.c0" text="Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection">
    <entity charOffset="129-144" id="131902a67f5e00ae13b9239427325dfd53413349.c0.e0" ontology_id="DOID_934" text="Virus Infection" type="disease"/>
  </chunk>
  <chunk id="131902a67f5e00ae13b9239427325dfd53413349.c1" text="Respiratory syncytial virus (RSV) is the leading cause of pediatric viral respiratory tract infections. Neither vaccine nor effective antiviral therapy is available to prevent and treat RSV infection. Palivizumab, a humanized monoclonal antibody, is the only product approved to prevent serious RSV infection, but its high cost is prohibitive in low-income countries. Here, we aimed to identify an effective, safe, and affordable antiviral agent for pre-exposure prophylaxis (PrEP) of RSV infection in children at high risk. We found that maleic anhydride (ML)-modified human serum albumin (HSA), designated ML-HSA, exhibited potent antiviral activity against RSV and that the percentages of the modified lysines and arginies in ML-are correlated with such anti-RSV activity. ML-HSA inhibited RSV entry and replication by interacting with viral G protein and blocking RSV attachment to the target cells, while ML-HAS neither bound to">
    <entity charOffset="134-143" id="131902a67f5e00ae13b9239427325dfd53413349.c1.e0" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="430-439" id="131902a67f5e00ae13b9239427325dfd53413349.c1.e1" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="430-445" id="131902a67f5e00ae13b9239427325dfd53413349.c1.e2" ontology_id="CHEBI_22587" text="antiviral agent" type="chemical"/>
    <entity charOffset="539-555" id="131902a67f5e00ae13b9239427325dfd53413349.c1.e3" ontology_id="CHEBI_474859" text="maleic anhydride" type="chemical"/>
    <entity charOffset="633-642" id="131902a67f5e00ae13b9239427325dfd53413349.c1.e4" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="847-854" id="131902a67f5e00ae13b9239427325dfd53413349.c1.e5" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
  </chunk>
  <chunk id="131902a67f5e00ae13b9239427325dfd53413349.c2" text="Viruses 2015, 7 799 F protein, nor inhibited F protein-mediated membrane fusion. Intranasal administration of ML-HSA before RSV infection resulted in significant decrease of the viral titers in the lungs of mice. ML-HSA shows promise for further development into an effective, safe, affordable, and easy-to-use intranasal regimen for pre-exposure prophylaxis of RSV infection in children at high risk in both low-and high-income countries."/>
</document>
